 ambit product step
host investor meet new ceo mike roman cfo nick gangestad
evp health mike vale late last week hq overal near-term
estim remain pressur expect high end ep guidanc
come alongsid earn novemb investor meet think
manag abl outlin comprehens medium-term save
variou product effort also hear commerci
price custom manag benefit busi transform
on-going commit run effici balanc sheet appetit undertak
 seem higher buyback result acquisit pace remain subdu
mean current medium-term ep compound-annual-growth-rate goal reiter
new plan ep growth like support higher buyback cost
save product tailwind see year would expect major
growth acceler busi health make minor estim
manag clearli put consider thought focu
remain flattish mani multi-industri compani spend littl decid
alloc spend presum fairli straightforward quick exercis
non-organ order drive compani top-lin growth profil would
surpris see move adjac market autom perhap
industri larg softwar digit seem unlik well build scale
organ inorgan exist prioriti growth area auto
electrif grown sale past month
health expect transform divest activ
return equiti ttm
link barclay live interact chart
rel valuat compress substanti yet see
catalyst revers stock under-perform retain underweight rate
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
flow oper
valuat leverag metric
deceler due electron industri
price alreadi inflect posit expect
limit addit improv light
dividend hike buy-back guid see limit
option balanc sheet year
estim consensu
improv price perform industri
leverag continu electron strength
sharp declin consum electron market
combin moder demand healthcar
thought prioriti new ceo
organ growth invest rate like remain steadi although organ sale
growth prove sluggish rel rest multi-industri sector
manag confid organ innov approach compani
satisfactori suffici drive organ growth least industri product
medium-term remind re-invest higher rate sector
averag capital-expenditure compris sale manag remind us
consist high return margin underscor merit on-going invest
even top-lin growth rate volatil
invest capital-expenditure rest sector
accompani focus approach asid quantiti
invest spend portfolio ration exit low growth busi
limit technolog synergi rest compani seen much
unit high focu area deploy capital-expenditure also
view critic drive high organ sale growth instanc hike
 sale recent year paid focus drive
new growth platform rather simpli pour capit iter effort
augment pre-exist initi among major growth initi automot
electrif appear make particularli strong progress sale growth
past month hand push advanc wound
take time bear fruit longer cycl healthcar industri
priorit growth invest platform collect repres
address market opportun
automot electrificationadvanc wound careconnect safetydata centersstructur adhesivesfiltrationair qualitypopul healthtop prioriti growth barclay compani
digit develop enjoy discuss mr roman
topic digit develop two issu upper
echelon manag clearli focus iot digit
unlik make larg softwar acquisit partial done
year core compet area health inform system
ad talent develop front re-vamp data
scientist hire effort face natur competit larg firm other
extent reflect learn success compani move histor
hire best talent even industri consult financ may
theoret appeal time graduat
ep estim current guidanc rang
believ high end guid least could lower next month fx
expect headwind tailwind call
given end-august spot rate gross cost headwind year like
inclus tariff materi logist cost rather
headwind guid due broader chemic input propylen think
headwind least partial off-set price effort compani remain
adam price comfort cover cost headwind somewhat aid
busi transform expect gross price larger tailwind
lesser extent share buyback rais buy-back estim given
subdu share price compani tend quit judici front henc
buy-back spend drop late
compani organ sale growth outlook year overal unchang
rate guid outlook china auto wors juli build rate
like health growth like remain subdu due on-going
soft oral care drug deliveri unit electron trend plan despit
plethora neg news recent week among semi cap equip maker
highlight exposur greenfield chip plant build non-c devic unit
fairli small chip product volum signific driver product
abras materi cleans fluid datacent increasingli
import market non-c devic part electron
ep bridgestart ep volum price core growthrevers ident manag gain electron monitor gain divestitur divestitur oper earn commun note gain associ action exclud guidescott benefit yoy revers charg neutral guid septemb strateg invest footprint optim net fo savingsgrowth total portfolio footprint product busi bt footprintmanufactur sg guid assum remaind factor core incrementalsraw materi septemb guid tax rate guideshar guid higher end rang assum almost buybacknet flat step interest expens off-set revers debt tender chargeend ep guidanc barclay estimate exclud divest gain associ action barclay compani
initi thought
due issu financi guidanc mid-decemb expect broad
organ sale growth rang provid segment fairli similar
health growth may slightli faster although drug deliveri possibl oral care
unlik see v-shape rebound bar dramat chang macro condit
next three month fx estim ep headwind sale headwind
think cost save aggreg variou product effort busi
transform footprint optim provid increment ep tailwind
share buyback ep tailwind next year provid larger tailwind
ep bridgestart ep volum price core growthraw scott divestitur oper earn note gain associ action exclud bt footprint bt footprintfootprint consolid spend assum repeat assum ad tax tax rate assumedshar assum buy-back ep barclay compani
hear
expect major chang oper capit deploy approach
unveil investor meet mmm hq two month time
think manag unveil comprehens cost save busi
transform current goal footprint optim plan
current goal look earli think organ
growth d/sale capex/sal aspir larg similar current plan
balanc sheet becom lever recent year expect current
leverag profil maintain clear prefer oppos buyback
portfolio prune like compani exit worth sale recent
year top prioriti growth automot electrif advanc wound care
probabl larg unchang
updat busi transform footprint optim effort
program well track save associ bt expect reach
year end repres first year meaning net save
fo novemb investor meet expect manag guid toward
higher end bt save target well implement addit round
restructur action emphasi commerci also anticip
disclosur surround posit extern bt effort notabl
commerci customer-fac part improv price manag
savingsbusi transform servic oper bso share total contribut contribut save save cumul total compani save servic center gsc share total contribut contribut save save cumul total compani save chain center expertis coe share total contribut contribut save save cumul total compani save busi transform save busi transform cumul save transform cumul save consolidationshar total footprint consolid contribut footprint consolid contribut footprint consolid save footprint consolid save combin annual combin save total cumul save save yoy chang cumul combin save total cumul save barclay compani
health slight demand improv medium term outlook intact
health segment compris sale ebit contain five
princip busi unit two specd programmat pipelin
base drug deliveri health inform system three tend
consum short-cycl natur sever top prioriti growth
platform hing progress health segment includ advanc wound
popul health
remind health care largest busi unit medic solut
segment revenu compris infect prevent segment revenu skin
 wound segment revenu adjac segment
disclos earn call organ sale growth segment trend
toward low end origin target notabl area weak
drug deliveri us oral improv somewhat
drug deliveri trough mark end robust year up-cycl
drug deliveri busi reach number mileston pre-clin work secur
sever larg deal drug deliveri cycl time approach year demand
lumpi due regulatori approv time mileston achiev product
life-cycle time tough comp like mean organ sale decreas
anticip slight organ sale growth meaning
inflect
drug solut -infect solut -skin wound solut -med busi yoy organ changedrug busi yoy organ changedrug barclay compani
oral choppi condit us us oral care demand lacklust
last two year due consolid result shift distributor allianc
elong period destock chang consum psych possibl tie
aftermath financi crisi first two phenomena
theoret transitori consum demand unlik snap back unless see step-
real wage growth part due success prevent mainten lack
dental insur coverag us popul dental insur
outbound us po data suggest low-singl digit growth market overal clearli
challeng manag inventori level channel appear
success mani peer frequent complain de-stock even though
end-demand volatil partli result success area appear
win market share
spin-off dhr dental busi see report corp re-fang dental
 firepow juli expect alter competit landscap
instanc compet sybron independ compet
sybron insid decad expect major chang sybron
outsid year two
oral emerg market new technolog offer avenu growth respons
subdu domest demand continu invest intern eu oral
enjoy sale compound-annual-growth-rate low-mid singl digit emerg market oral demand
growth much higher well domest new technolog mmm strength
repair rather protect move part dental chain may see increas
effort two segment market protect market compani offer
clinpro toothpast brand instanc move segment clariti clear
align launch month ago receiv posit recept market
case start grow rapidli manag believ lot space market
cite full suit orthodont point differenti practition
attract growth opportun acknowledg issu
present market today solv clear align technolog lower
align estim view product anoth tool tool kit
combin clear align tradit brace provid give
practition option manag perspect
profit reinvest clear prioriti may step-up continu
balanc act manag feel comfort current level profit health
ebit margin remind healthcar reinvest
revenu toward compani averag attract growth
inhal drug deliveri opportun advanc wound care
opportun next two year model increment margin expect
ebit margin
 think lack activ may also put upward pressur organ
health mani health care compani acquir consist buy
outsid lack access target one reason struggl
acquir industri view think could see segment
increas mr roman tenur ceo wherea mr thulin last
year ceo went toward safeti graphic
run effici balanc sheet recent year nd/ebitda rise
year-end estim think current leverag
level like remain steadi medium-term guid flexibl
deploy plan think compani could guid
dividend debt asset sale ratio pay-out ratio ebitda ratio ex-r ad leverag dcapexdividendpensionavail bn barclay compani
 appetit abil integr deal mr gangestad note
amount sinc lower compani expect laid
current medium-term plan sound mr roman ceo may look rectifi
competit deal come strateg peer rather
privat equiti appetit acquisit appear high prioriti capit
deploy organ growth aspir remain deal least earn
cost capit within five year transact compani built
central deal integr approach recent year less discret busi unit
head opposit approach compani cover
manag confid deal integr synergi gener high
compar past
 larger deal possibl adjac market may appeal continu
 process sens larger deal prefer rather dozen small one
deal size remain promis term pipelin transact
like happen clear willing larger one howev
think transform unlik new ceo like
transact within industri health predominantli add
growth platform healthcar advanc wound care oral care
build posit adjac market oppos simpli ad market share
adhes exampl market current involv fairli minor way
manag may interest expand presenc includ factori
autom robot view
barclay research compani data unit multipl per share unless otherwis specifi
barclay research compani data unit
incom expens tax tax dilut current total current total current portion long-term trade current current lt lt total sharehold total liabil sharehold barclay compani
barclay research compani data unit
barclay research compani data unit
incom inc chang work flow cash flow flow flow total cash safeti electron total yoy revenu safeti electron segment oper ebit increment segment increment barclay compani
graphicselectron energyhealth consumerseg totalsal oper end-market splitadhes tape transport abras advanc mat ls filtrat aerospac safeti traffic safeti secur commerci solut roof granul matl system electron matl solut electr market telecom renew energi deliveri food safeti health sy medic solut oral stationeri offic consum health soldindustri abras autobodi repair solut care do-it-yourself tape filtrat purif system specialti addit tape fastern person hygien respiratori hear eye protect reflect signag graphic film advertis roof granul asphalt shingl identif issuanc authent build safeti solut surfac light design optic clear adhes transport solut flexibl circuit electron compon manag film lcd electr tape medium voltag cabl accessori oem insul tape telecommun copper splice fiber splicing/connect skin wound care infect prevent patient warm solut oral care solut code reimburs softwar drug deliveri food safeti indic solutionsconsum tape reposition note air filtrat clean product home consum bandag brace support retail abras divis headjim baumanfrank littleashish khandpurmichael valejoaquin delgadomajor brandsscotch-weld meguiar bondo vhb cubitron ii filtretescotchprint thinsul speedgla peltor diamond grade scotch-brit envis graphicsviku scotch super tartannexcar littmann clintrac tegadermscotch tape scotch-brit scotch gard post-it commandcompetitorsdanah illinoi tool work pentairmsa safeti honeywel systemsillinoi tool work amphenol johnson johnson danaherproct gambl church dwight newel distributiongeograph sale split unit splitunit move consum cycl market split barclay compani
julian mitchel herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
